Medicine
Bizengri 375 mg/18.75 mL injection
Bizengri 375 mg/18.75 mL injection is a prescription medicine containing Zenocutuzumab for intravenous use, marketed by Merus, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to…
Key facts
- Active ingredient (INN)
- Zenocutuzumab
- Brand
- Bizengri
- Strength
- 375 mg/18.75 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 2 vials of 18.75 mL
- Marketing authorisation holder
- Merus
- Manufacturers
- MerusPartner Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 December 2024
- Identifiers
- RxCUI 2699594, 2699601DailyMed set ID 2a33e782-fc75-4dba-b77c-a44536ac13a5, 203daea4-fc87-40a4-a92f-ba2351b16de1NDC 83077-100, 71837-1000Application BLA761352
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 vial, glass in 1 carton / 18.75 mL in 1 vial, glass | 83077-100-02 | Merus | 4 December 2024 |
| 2 vial, glass in 1 carton / 18.75 mL in 1 vial, glass | 71837-1000-2 | Partner Therapeutics | 16 December 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 4 December 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Zenocutuzumab is a prescription medicine indicated for the treatment of adults with advanced, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Zenocutuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZenocutuzumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BIZENGRI prescribing information (Partner Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Bizengri 375 mg/18.75 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.